Becton, Dickinson and Co. (BD) reported good news Thursday, as it saw quarterly revenues of $4.784 billion for its fourth fiscal quarter, an increase of 4.4% over the prior-year period. Of note, the company’s life sciences segment saw worldwide revenues of $1.488 billion, representing an increase of 31.2% over the prior-year period as reported, or 31.4% on a currency-neutral basis.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 3D Systems, Avinger, Eurofins Scientific, Oxford Immunotec, Pear Therapeutics, Sectra, Veracyte.
The U.S. FDA’s stated policy is that it will not review emergency use authorizations (EUAs) for lab-developed tests (LDTs) for the COVID-19 pandemic, but that doesn’t mean labs are completely shut out. The FDA’s Toby Lowe said that a lab that wants to pair an assay that already has an EUA with a new software installation on lab instrumentation can work with the assay developer to update that EUA.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Applied UV, Axsome Therapeutics, Clinical Laserthermia Systems, Digirad, Electromedical Technologies, Energetic Wellness School of Naturopathy, The Feinstein Institutes for Medical Research, Mimedx, Novan, Ontrak, Stryker, Thermo Fisher Scientific, Toyoda Gosei, Wright Medical Group.
Keeping you up to date on recent developments in orthopedics, including: New opportunities for detecting osteoporosis; Brazilian researchers discover how muscle regenerates after exercise; Different outcomes by race/ethnicity among patients with COVID-19 and rheumatic disease.
HONG KONG – Humanigen Inc. has executed its first licensing agreement in the Asia-Pacific region, in a deal worth up to $20 million that gives Telcon RF Pharmaceutical Inc. and KPM Tech Co. Ltd. the development and commercialization rights to lenzilumab for COVID-19 in South Korea and the Philippines.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Axsome, Bristol, Equillium, Generex, Ionis, Jubilant, Myokardia, Novan, Novavax, Ocular, Pfizer, Prothena, Salliant, Sofie.